Results 1 to 10 of about 1,879,389 (356)
Use of the SGLT2 inhibitor canagliflozin for control of refractory equine hyperinsulinemia and laminitis [PDF]
Background: Hyperinsulinemia associated with pituitary pars intermedia dysfunction (PPID) and/or equine metabolic syndrome (EMS) is well documented to put horses at high risk of laminitis.
Eleanor M. Kellon, Kathleen M. Gustafson
doaj +1 more source
Summary: Human subcutaneous adipocytes are an attractive therapeutic target in regulating overall physiological homeostasis. However, the differentiation of primary human adipose-derived models remains challenging.
Ajit Regmi, William Roell
doaj +1 more source
Molecular and Cellular Bases of Lipodystrophy Syndromes
Lipodystrophy syndromes are rare diseases originating from a generalized or partial loss of adipose tissue. Adipose tissue dysfunction results from heterogeneous genetic or acquired causes, but leads to similar metabolic complications with insulin ...
Jamila Zammouri +20 more
doaj +1 more source
Hypertriglyceridemia in equines with refractory hyperinsulinemia treated with SGLT2 inhibitors
Background: Sodium-Glucose CoTransporter-2 [SGLT2] inhibitors, the -flozin group of drugs, which block glucose reuptake in the renal proximal tubule, are being increasingly used off-label to treat horses with refractory hyperinsulinemia. After two years
Eleanor M. Kellon, Kathleen M. Gustafson
doaj +1 more source
Possible dysmetabolic hyperferritinemia in hyperinsulinemic horses [PDF]
Background: Hyperinsulinemia associated with equine metabolic syndrome (EMS) and pituitary pars intermedia dysfunction (PPID) is a risk factor for laminitis.
Eleanor M. Kellon, Kathleen M. Gustafson
doaj +1 more source
Heterozygous loss-of-function variants of the glucokinase (GCK) gene are responsible for a subtype of maturity-onset diabetes of the young (MODY). GCK-MODY is characterized by a mild hyperglycemia, mainly due to a higher blood glucose threshold for ...
José Timsit +14 more
doaj +1 more source
Dunnigan syndrome, or Familial Partial Lipodystrophy type 2 (FPLD2; ORPHA 2348), is a rare autosomal dominant disorder due to pathogenic variants of the LMNA gene. The objective of the French National Diagnosis and Care Protocol (PNDS; Protocole National
H. Mosbah +36 more
doaj +1 more source
The pathogenesis of type 2 diabetes is characterized by insulin resistance, primarily in skeletal muscle, fat and liver, and a relative failure of the pancreatic b-cell (1, 2). Considerable controversy surrounds the issue of which of these deficiencies is the primary cause of diabetes.
openaire +2 more sources
Background In humans and animal models, excessive intake of dietary fat, fructose and cholesterol has been linked to the development of non-alcoholic fatty liver disease (NAFLD). However, the individual roles of the dietary components remain unclear.
Victoria Svop Jensen +7 more
doaj +1 more source
Insulin infusion sets associated with adverse events: strategies for improved diabetes education
IntroductionInsulin Infusion Sets (IIS) play a crucial role in ensuring the safe delivery of insulin through a Continuous Subcutaneous Insulin Infusion (CSII) for individuals with Type 1 Diabetes (T1D). Recent advancements in therapy have highlighted the
Ana Lucia Domingues Neves +12 more
doaj +1 more source

